FTC and seven states ask judge to hold Martin Shkreli in contempt
The FTC and seven states say Martin Shkreli repeatedly broke his lifetime ban from the pharmaceutical industry, and they want a judge to hold him in contempt.
The Federal Trade Commission and seven U.S. states allege that Martin Shkreli repeatedly violated a lifetime ban from the pharmaceutical industry. They have asked a judge to hold him in contempt.
The Guardian reports the motion was filed Tuesday in U.S. district court in New York City. It alleges that Shkreli, 43, has bought and sold shares in at least 60 pharma companies since leaving prison in May 2022. It also alleges he has commented publicly on how those companies operate.
The Guardian says the conditions of his 2022 release bar him from the industry, including owning stakes or taking part in business decisions.
CNBC reports the ban followed a trial. The trial found he organized an illegal scheme to maintain a monopoly on the drug Daraprim.
Reported by
- CNBCMartin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claimTue, Oct 13, 9:19 AM EDT
- The GuardianFTC and seven states seek contempt ruling against Shkreli over pharma banTue, Oct 13, 12:54 PM EDT
- The HillFTC: 'Pharma bro' Shkreli violated lifetime industry ban, should be held in contemptTue, Oct 13, 1:05 PM EDT
- The New York TimesMartin Shkreli Violated Lifetime Ban From Drug Industry, U.S. SaysTue, Oct 13, 2:48 PM EDT
- Ars TechnicaMartin Shkreli livestreamed himself violating lifetime pharma ban, FTC saysTue, Oct 13, 6:48 PM EDT
This story was written by AI using only the reports listed above, and published without a person reviewing it first. It is rewritten as new reports arrive. Read the original reporting for full detail. Spot an error? Tell us.